Prime Minister shares an article on India’s growing self-reliant med-tech ecosystem

India's journey towards self-reliance in medical technology represents a transformative shift in the country's healthcare landscape, marking a significant milestone under the Atmanirbhar Bharat initiative launched in May 2020. The Prime Minister's sharing of Union Health Minister JP Nadda's article on August 8, 2026, underscores the government's commitment to reducing India's historical dependence on imported medical devices, which once accounted for nearly 80% of the domestic market. This strategic pivot gained momentum during the COVID-19 pandemic, which exposed critical vulnerabilities in global supply chains and highlighted the urgent need for indigenous manufacturing capabilities in essential medical equipment such as ventilators, PPE kits, diagnostic kits, and imaging devices. The key policy instruments driving this transformation include the Production Linked Incentive (PLI) scheme for medical devices, notified in March 2020 with an outlay of ₹3,420 crore, and the establishment of Medical Device Parks in Himachal Pradesh, Madhya Pradesh, Tamil Nadu, and Uttar Pradesh with a combined financial assistance of ₹400 crore. These initiatives operate within the constitutional framework of Article 21 (Right to Life and Personal Liberty), which the Supreme Court has interpreted to include the right to health, and Article 47 (Directive Principle) mandating the state to improve public health. The National Medical Devices Policy, 2023, further provides a comprehensive regulatory roadmap aligned with the Drugs and Cosmetics Act, 1940, and the Medical Devices Rules, 2017, ensuring quality standards while promoting ease of doing business. Stakeholders in this ecosystem span multiple levels: the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers serves as the nodal agency, while the Central Drugs Standard Control Organization (CDSCO) regulates quality and safety. State governments facilitate land allocation and infrastructure for Medical Device Parks, and industry players — from large conglomerates like Tata Medical and Diagnostics to innovative startups incubated under the National Health Mission — drive R&D and manufacturing. The National Health Authority's integration of domestically produced devices into the Ayushman Bharat Digital Mission creates assured demand, while international partnerships with countries like Japan, Germany, and the USA enable technology transfer and regulatory harmonization. Economically, the sector is projected to grow from $11 billion in 2022 to $50 billion by 2030, generating significant employment and export potential. Politically, it strengthens India's strategic autonomy in health security and positions the country as a reliable supplier to the Global South, aligning with the 'Vasudhaiva Kutumbakam' philosophy articulated during India's G20 presidency in 2023. Socially, indigenous production reduces costs — exemplified by the dramatic price reduction of coronary stents (capped at ₹30,000 in 2017) and knee implants — making advanced healthcare accessible to millions under Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (PM-JAY). Looking ahead, the focus will likely shift towards high-end innovation in AI-driven diagnostics, robotic surgery, implantable devices, and personalized medicine. The recently announced National Research Foundation (NRF) with a ₹50,000 crore corpus over five years (2023-28) could catalyze breakthrough R&D. However, challenges remain: strengthening the regulatory framework to match global standards (like US FDA or EU MDR), bridging the skill gap in biomedical engineering, ensuring sustainable financing for startups, and addressing intellectual property barriers. Success in this domain will not only fulfill the constitutional promise of health for all but also establish India as a credible 'pharmacy of the world' extending into 'med-tech hub of the world', reinforcing its leadership in affordable healthcare innovation globally.